NASDAQ:JAGX

Jaguar Health Competitors

$1.35
+0.11 (+8.87 %)
(As of 04/21/2021 02:28 PM ET)
Add
Compare
Today's Range
$1.19
Now: $1.35
$1.38
50-Day Range
$1.30
MA: $1.88
$2.25
52-Week Range
$0.19
Now: $1.35
$4.47
Volume109,827 shs
Average Volume31.87 million shs
Market Capitalization$175.54 million
P/E RatioN/A
Dividend YieldN/A
Beta1.83

Competitors

Jaguar Health (NASDAQ:JAGX) Vs. VERU, KDNY, GOSS, RIGL, ALBO, and ANAB

Should you be buying JAGX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Jaguar Health, including Veru (VERU), Chinook Therapeutics (KDNY), Gossamer Bio (GOSS), Rigel Pharmaceuticals (RIGL), Albireo Pharma (ALBO), and AnaptysBio (ANAB).

Jaguar Health (NASDAQ:JAGX) and Veru (NASDAQ:VERU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Valuation & Earnings

This table compares Jaguar Health and Veru's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jaguar Health$5.78 million30.37$-38,540,000.00($6.89)-0.20
Veru$42.59 million15.50$-18,970,000.00($0.11)-83.45

Veru has higher revenue and earnings than Jaguar Health. Veru is trading at a lower price-to-earnings ratio than Jaguar Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Jaguar Health and Veru's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jaguar Health-372.81%-659.73%-76.08%
Veru-44.55%-23.72%-13.80%

Volatility & Risk

Jaguar Health has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, Veru has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Jaguar Health and Veru, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jaguar Health0000N/A
Veru00503.00

Veru has a consensus target price of $19.20, indicating a potential upside of 110.30%. Given Veru's higher probable upside, analysts clearly believe Veru is more favorable than Jaguar Health.

Insider & Institutional Ownership

1.4% of Jaguar Health shares are owned by institutional investors. Comparatively, 23.3% of Veru shares are owned by institutional investors. 3.2% of Jaguar Health shares are owned by company insiders. Comparatively, 26.1% of Veru shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Veru beats Jaguar Health on 10 of the 13 factors compared between the two stocks.

Jaguar Health (NASDAQ:JAGX) and Chinook Therapeutics (NASDAQ:KDNY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Jaguar Health and Chinook Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jaguar Health0000N/A
Chinook Therapeutics00803.00

Chinook Therapeutics has a consensus target price of $30.3333, indicating a potential upside of 101.68%. Given Chinook Therapeutics' higher probable upside, analysts clearly believe Chinook Therapeutics is more favorable than Jaguar Health.

Profitability

This table compares Jaguar Health and Chinook Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jaguar Health-372.81%-659.73%-76.08%
Chinook Therapeutics-215.80%-112.72%-21.36%

Insider & Institutional Ownership

1.4% of Jaguar Health shares are owned by institutional investors. 3.2% of Jaguar Health shares are owned by company insiders. Comparatively, 5.9% of Chinook Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Jaguar Health and Chinook Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jaguar Health$5.78 million30.37$-38,540,000.00($6.89)-0.20
Chinook Therapeutics$17.26 million36.95$-82,370,000.00($5.15)-2.92

Jaguar Health has higher earnings, but lower revenue than Chinook Therapeutics. Chinook Therapeutics is trading at a lower price-to-earnings ratio than Jaguar Health, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Jaguar Health has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, Chinook Therapeutics has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500.

Summary

Chinook Therapeutics beats Jaguar Health on 9 of the 13 factors compared between the two stocks.

Gossamer Bio (NASDAQ:GOSS) and Jaguar Health (NASDAQ:JAGX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Institutional & Insider Ownership

72.0% of Gossamer Bio shares are owned by institutional investors. Comparatively, 1.4% of Jaguar Health shares are owned by institutional investors. 23.3% of Gossamer Bio shares are owned by company insiders. Comparatively, 3.2% of Jaguar Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Gossamer Bio and Jaguar Health, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gossamer Bio00503.00
Jaguar Health0000N/A

Gossamer Bio presently has a consensus price target of $23.00, suggesting a potential upside of 177.44%. Given Gossamer Bio's higher possible upside, research analysts clearly believe Gossamer Bio is more favorable than Jaguar Health.

Risk & Volatility

Gossamer Bio has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, Jaguar Health has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500.

Earnings and Valuation

This table compares Gossamer Bio and Jaguar Health's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gossamer BioN/AN/A$-180,310,000.00($3.29)-2.53
Jaguar Health$5.78 million30.37$-38,540,000.00($6.89)-0.20

Jaguar Health has higher revenue and earnings than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than Jaguar Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Gossamer Bio and Jaguar Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gossamer BioN/A-64.34%-46.52%
Jaguar Health-372.81%-659.73%-76.08%

Summary

Gossamer Bio beats Jaguar Health on 8 of the 12 factors compared between the two stocks.

Rigel Pharmaceuticals (NASDAQ:RIGL) and Jaguar Health (NASDAQ:JAGX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Valuation & Earnings

This table compares Rigel Pharmaceuticals and Jaguar Health's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rigel Pharmaceuticals$59.29 million10.42$-66,890,000.00($0.40)-9.08
Jaguar Health$5.78 million30.37$-38,540,000.00($6.89)-0.20

Jaguar Health has lower revenue, but higher earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Jaguar Health, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Rigel Pharmaceuticals has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, Jaguar Health has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Rigel Pharmaceuticals and Jaguar Health, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rigel Pharmaceuticals01302.75
Jaguar Health0000N/A

Rigel Pharmaceuticals presently has a consensus target price of $8.3333, suggesting a potential upside of 130.84%. Given Rigel Pharmaceuticals' higher possible upside, research analysts plainly believe Rigel Pharmaceuticals is more favorable than Jaguar Health.

Profitability

This table compares Rigel Pharmaceuticals and Jaguar Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rigel Pharmaceuticals-26.25%-44.96%-20.08%
Jaguar Health-372.81%-659.73%-76.08%

Institutional & Insider Ownership

82.0% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 1.4% of Jaguar Health shares are held by institutional investors. 4.7% of Rigel Pharmaceuticals shares are held by company insiders. Comparatively, 3.2% of Jaguar Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Rigel Pharmaceuticals beats Jaguar Health on 9 of the 13 factors compared between the two stocks.

Jaguar Health (NASDAQ:JAGX) and Albireo Pharma (NASDAQ:ALBO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.

Valuation & Earnings

This table compares Jaguar Health and Albireo Pharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jaguar Health$5.78 million30.37$-38,540,000.00($6.89)-0.20
Albireo Pharma$9.64 million62.79$-62,720,000.00($5.04)-6.28

Jaguar Health has higher earnings, but lower revenue than Albireo Pharma. Albireo Pharma is trading at a lower price-to-earnings ratio than Jaguar Health, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Jaguar Health has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, Albireo Pharma has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Jaguar Health and Albireo Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jaguar Health0000N/A
Albireo Pharma00803.00

Albireo Pharma has a consensus price target of $72.00, indicating a potential upside of 128.64%. Given Albireo Pharma's higher probable upside, analysts plainly believe Albireo Pharma is more favorable than Jaguar Health.

Profitability

This table compares Jaguar Health and Albireo Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jaguar Health-372.81%-659.73%-76.08%
Albireo Pharma-751.53%-71.22%-42.91%

Institutional and Insider Ownership

1.4% of Jaguar Health shares are held by institutional investors. Comparatively, 85.7% of Albireo Pharma shares are held by institutional investors. 3.2% of Jaguar Health shares are held by insiders. Comparatively, 5.0% of Albireo Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Albireo Pharma beats Jaguar Health on 9 of the 13 factors compared between the two stocks.

Jaguar Health (NASDAQ:JAGX) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Jaguar Health and AnaptysBio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jaguar Health0000N/A
AnaptysBio13302.29

AnaptysBio has a consensus price target of $30.2857, indicating a potential upside of 37.60%. Given AnaptysBio's higher probable upside, analysts plainly believe AnaptysBio is more favorable than Jaguar Health.

Valuation & Earnings

This table compares Jaguar Health and AnaptysBio's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jaguar Health$5.78 million30.37$-38,540,000.00($6.89)-0.20
AnaptysBio$8 million76.21$-97,340,000.00($3.60)-6.19

Jaguar Health has higher earnings, but lower revenue than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Jaguar Health, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

1.4% of Jaguar Health shares are held by institutional investors. 3.2% of Jaguar Health shares are held by insiders. Comparatively, 13.0% of AnaptysBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Jaguar Health has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500.

Profitability

This table compares Jaguar Health and AnaptysBio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jaguar Health-372.81%-659.73%-76.08%
AnaptysBioN/A-19.09%-17.94%

Summary

AnaptysBio beats Jaguar Health on 9 of the 13 factors compared between the two stocks.


Jaguar Health Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Veru logo
VERU
Veru
1.4$9.18+3.3%$638.58 million$42.59 million-32.78Analyst Report
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$15.05+2.5%$621.67 million$17.26 million-4.18Analyst Revision
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.31+1.3%$619.33 millionN/A-2.33Increase in Short Interest
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.63+2.2%$603.93 million$59.29 million-24.20Increase in Short Interest
News Coverage
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$31.67+0.5%$602.28 million$9.64 million-5.16
AnaptysBio logo
ANAB
AnaptysBio
1.5$22.28+1.7%$599.59 million$8 million-8.22
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$19.07+2.7%$598.75 millionN/A-10.14Analyst Report
Clovis Oncology logo
CLVS
Clovis Oncology
1.2$5.93+4.4%$592.69 million$143.01 million-1.13
SIGA Technologies logo
SIGA
SIGA Technologies
0.3$7.55+0.3%$581.37 million$26.74 million18.88
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$34.47+0.6%$580.62 millionN/A-15.96
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$11.40+4.9%$578.15 millionN/A-4.58Analyst Upgrade
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$23.98+1.5%$573.91 million$12.69 million-11.53News Coverage
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.0$42.98+0.3%$566.61 million$195.89 million122.80
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$17.35+4.6%$546.63 million$1.19 million-7.23Gap Down
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.33+2.6%$543.69 millionN/A-5.33Gap Down
OrganiGram logo
OGI
OrganiGram
1.6$2.54+7.9%$543.51 million$64.61 million-3.74Analyst Report
Decrease in Short Interest
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24+0.0%$531.75 millionN/A-3.15
IVERIC bio logo
ISEE
IVERIC bio
1.5$6.03+3.2%$526.59 millionN/A-4.79
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.4$11.66+5.5%$523.94 millionN/A-9.04
89bio logo
ETNB
89bio
1.6$27.72+6.9%$517.10 millionN/A-5.49Analyst Report
Insider Selling
News Coverage
Gap Down
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$8.41+5.4%$515.68 million$57.49 million-7.07Gap Up
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$11.22+5.4%$515.18 millionN/A-5.75Analyst Upgrade
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$21.26+2.9%$513.23 millionN/A-8.37
Inventiva logo
IVA
Inventiva
0.0$13.27+0.9%$512.62 millionN/A0.00
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$12.12+0.7%$509.61 million$25 million-18.65News Coverage
Gap Up
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$14.24+2.7%$507.37 millionN/A-4.10
Akouos logo
AKUS
Akouos
1.6$13.81+5.7%$502.27 millionN/A0.00
Provention Bio logo
PRVB
Provention Bio
1.6$7.91+1.3%$494.96 millionN/A-5.31Analyst Report
Increase in Short Interest
XBiotech logo
XBIT
XBiotech
1.0$16.67+1.1%$485.48 millionN/A1.16News Coverage
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$13.40+0.7%$484.34 million$58.12 million-15.58
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.34+1.9%$478.24 million$59.22 million41.70
AC Immune logo
ACIU
AC Immune
1.3$6.85+5.0%$468.31 million$111.75 million-7.61Analyst Upgrade
Analyst Revision
News Coverage
Verastem logo
VSTM
Verastem
1.1$2.82+3.9%$465.22 million$17.46 million-2.00
Evolus logo
EOLS
Evolus
1.3$11.78+10.4%$461.38 million$34.92 million-5.80
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.17+0.0%$460.03 million$49.65 million-1.65
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.48+2.0%$455.79 million$102.31 million6.69Increase in Short Interest
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$34.15+2.8%$448.50 million$40,000.00-1.48Upcoming Earnings
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$5.94+2.2%$448.40 millionN/A-12.12
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$2.99+2.7%$447.35 million$109.33 million-2.20
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.62+7.7%$446.17 million$22.27 million-4.23Analyst Report
Insider Buying
Analyst Revision
News Coverage
Gap Down
Geron logo
GERN
Geron
1.4$1.44+2.8%$445.94 million$460,000.00-4.11Decrease in Short Interest
Verona Pharma logo
VRNA
Verona Pharma
1.7$7.94+4.5%$439.15 millionN/A-2.41News Coverage
Altimmune logo
ALT
Altimmune
1.9$12.22+3.4%$438.74 million$5.80 million-6.14
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.8$2.91+2.7%$434.41 million$335 million-0.98
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.7$7.63+8.1%$431.48 million$6.07 million-3.65News Coverage
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.6$8.73+1.4%$429.85 million$72.96 million-2.83Analyst Report
News Coverage
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8$16.86+2.1%$429.41 millionN/A-3.54
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$5.39+4.5%$427.02 million$56.50 million0.00
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$18.72+3.5%$423.99 millionN/A0.00Gap Down
BCEL
Atreca
1.7$11.82+3.5%$420.24 millionN/A-4.19Unusual Options Activity
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.